- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03252730
In-Use Test With a Cosmetic Product
August 17, 2017 updated by: Dr. August Wolff GmbH & Co. KG Arzneimittel
In-Use Test With a Cosmetic Product (WO 4260) for Topical Use on the Scalp
The aim of the study is to evaluate the tolerance of the product WO 4260 by a dermatologist.
Additional objectives of this clinical in-use study are to evaluate the cosmetic features and acceptance of the product by means of a questionnaire in an interview situation and by skin hydration measurements on the scalp.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hamburg, Germany, 20354
- SIT Skin Investigation and Technology Hamburg GmbH
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age: ≥ 18 years
- sex: approx. 50% male and approx. 50% female
- users of hair tonic for dry scalp
- dry, itchy scalp prone to atopic eczema / atopic dermatitis
Exclusion Criteria:
- any deviation from the above-mentioned criteria
- users of sour hair rinse
- subjects who wash their hair more than once a day
- other dermatological disorders (scars, moles) on the scalp
- known incompatibilities to cosmetics and ingredients of cosmetic test products (please see INCI)
- topical medication in the test area within 1 month prior to study start
- systemic medication with anti-inflammatory agents and antibiotics within 2 weeks prior to starting of the study
- systemic medication with retinoids, antihistamines and/or immunomodulators (e.g. cortisone, corticosterone, chemotherapeutic agents) within 4 weeks prior to starting of the study
- systemic illness of the subject at the beginning of the study
- pregnancy and period of breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: WO 4260 Cosmetic Product for Topical Use
WO 4260 is used to treat dry and itchy scalp
|
Application on the hair scalp at least once a day over four weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tolerance of the Test Product on the Scalp
Time Frame: after 4 weeks of treatment
|
Change from Baseline Tolerance on the Scalp at 4 weeks
|
after 4 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin Hydration of the Scalp
Time Frame: before product treatment; after 2 and 4 weeks of treatment
|
The measurement is performed using the DermaLab® device with the moisture pin (Cortex Technology)
|
before product treatment; after 2 and 4 weeks of treatment
|
|
Performance of the Test Product
Time Frame: after 4 weeks of treatment
|
Subjective assessment of product performance in a questionnaire-based interview
|
after 4 weeks of treatment
|
|
Tolerance of the Test Product on the Scalp
Time Frame: after 2 weeks of treatment
|
Dermatological assessment of the Scalp concerning the Tolerance of the Test Product regarding erythema, edema dryness etc.
Each item is scored 0=absent to 4=extreme.
|
after 2 weeks of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Mona Mazinani, MD, SIT Skin Investigation and Technology Hamburg GmbH
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 30, 2017
Primary Completion (Actual)
February 27, 2017
Study Completion (Actual)
February 27, 2017
Study Registration Dates
First Submitted
July 18, 2017
First Submitted That Met QC Criteria
August 16, 2017
First Posted (Actual)
August 17, 2017
Study Record Updates
Last Update Posted (Actual)
August 22, 2017
Last Update Submitted That Met QC Criteria
August 17, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LPT-15/2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatitis, Atopic
-
Caja Costarricense de Seguro SocialNot yet recruitingAtopic Dermatitis | Atopic Dermatitis (Eczema) | Atopic Dermatitis (AD) | Atopic Dermatitis / Eczema | Atopic Dermatitis, Unspecified | Atopic Dermatitis PatientsCosta Rica
-
Alphyn BiologicsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis (Eczema) | Atopic Dermatitis Eczema | Eczema, Atopic | Atopic Dermatitis (AD)Australia
-
En Chu Kong HospitalRecruitingSkin Diseases | Skin Diseases, Genetic | Skin Diseases, Eczematous | Atopic Dermatitis | Atopic Dermatitis (Eczema) | Atopic Dermatitis Eczema | Atopic Dermatitis (AD) | TCMTaiwan
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Taipei Medical University Shuang Ho HospitalRecruitingAtopic Dermatitis (Eczema) | Atopic Dermatitis, ProbioticsTaiwan
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
Apollo Therapeutics LtdRecruitingDermatitis | Eczema | Dermatitis, Atopic | Atopic Dermatitis | Atopic | Eczema, Atopic | Dermatologic Disease | Eczema Atopic DermatitisUnited States, Spain, Germany, Canada, Bulgaria, Poland, Czechia, Hungary
-
PfizerTerminatedEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
Corvus Pharmaceuticals, Inc.RecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Eczema, AtopicUnited States
-
Evommune, Inc.CompletedEczema | Atopic Dermatitis (AD) | Eczema Atopic DermatitisNew Zealand, Australia
Clinical Trials on WO 4260 Cosmetic Product for Topical Use
-
Dr. August Wolff GmbH & Co. KG ArzneimittelSIT Skin Investigation and Technology Hamburg GmbHCompleted
-
Dr. August Wolff GmbH & Co. KG ArzneimittelproDERM Institut für Angewandte Dermatologische Forschung GmbH; Microscopy...Completed
-
Cosmetique Active InternationalCompletedHealthy Volunteers | Hyperpigmentation | Skin PigmentationRomania
-
Hannover Medical SchoolCompletedEqually of Delivery Systems of Local Anesthesia in BronchoscopyGermany
-
Swedish Match ABCompletedCigarette SmokingUnited States
-
Johnson & Johnson Consumer Inc. (J&JCI)Completed
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
University of Colorado, BoulderUniversity of Colorado, DenverCompletedObesity | Type 2 Diabetes | Cannabis Use | Insulin SensitivityUnited States
-
Sukma Skin TreatmentCompletedAcne VulgarisIndonesia
-
Direction Centrale du Service de Santé des ArméesCompletedHyperhidrosis | Residual LimbsFrance